Clinical trial NCT00036088: Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Schizophrenia
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2002-05-08
Enrollment: 530
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia


Eligibility criteria: Inclusion:

1. You must be between the ages of 18 and 75. If you have reached your 76th birthday, you will not be able to participate
2. You must have been diagnosed with schizophrenia
3. You must be able to visit the doctor's office as scheduled for the next 7 months

Exclusion:

1. You have a serious medical illness, such as heart, liver, or kidney disease (Note: If you are uncertain about a particular condition, discuss it with your doctor.)
2. You are either pregnant or breastfeeding

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: El Centro
country: United States
state: California
city: Glendale
country: United States
state: California
city: Sherman Oaks
country: United States
state: California
city: Middleton
country: United States
state: Connecticut
city: Norwich
country: United States
state: Connecticut
city: Melbourne
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: Atlanta
country: United States
state: Georgia
city: Chicago
country: United States
state: Illinois
city: Hoffman Estates
country: United States
state: Illinois
city: Lafayette
country: United States
state: Indiana
city: Rockville
country: United States
state: Maryland
city: Newton
country: United States
state: Massachusetts
city: St Charles
country: United States
state: Missouri
city: New York
country: United States
state: New York
city: Olean
country: United States
state: New York
city: Staten Island
country: United States
state: New York
city: Cincinnati
country: United States
state: Ohio
city: Portland
country: United States
state: Oregon
city: Philadelphia
country: United States
state: Pennsylvania
city: Austin
country: United States
state: Texas
city: El Paso
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: Terrell
country: United States
state: Texas
city: Richmond
country: United States
state: Virginia
city: La Plata
country: Argentina
state: Buenos Aires
city: Godoy Cruz
country: Argentina
state: Mendoza
city: Buenos Aires
country: Argentina
city: Ciudad De Buenos Air
country: Argentina
city: Graz
country: Austria
city: Innsbruck
country: Austria
city: Linz
country: Austria
city: Wein
country: Austria
city: Wels
country: Austria
city: Salvador
country: Brazil
state: Bahia
city: Aparecida De Goiania
country: Brazil
state: Goias
city: Pelotas
country: Brazil
state: RS
city: Rio De Janeiro
country: Brazil
city: Sau Paulo
country: Brazil
city: Essen
country: Germany
city: Hamburg
country: Germany
city: Tubingen
country: Germany
city: Dublin
country: Ireland
city: Mexico City
country: Mexico
city: Lima
country: Peru
city: Cidra
country: Puerto Rico
city: Ponce
country: Puerto Rico
city: Rio Piedras
country: Puerto Rico
city: San Juan
country: Puerto Rico
city: Sama De Langreo
country: Spain
state: Asturias
city: San Boi De Llobregat
country: Spain
state: Barcelona
city: Elizondo
country: Spain
state: Navarra
city: Pamplona
country: Spain
state: Navarra
city: Barcelona
country: Spain
city: Camberwell
country: United Kingdom
state: London
city: Kings Lynn
country: United Kingdom
state: Norfolk
city: Paisley
country: United Kingdom
state: Scotland
city: Guildford
country: United Kingdom
state: Surrey
city: London
country: United Kingdom
city: Caracas
country: Venezuela
Study officials:
References:
citation: Liu-Seifert H, Ascher-Svanum H, Osuntokun O, Jen KY, Gomez JC. Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics. BMC Psychiatry. 2011 May 17;11:87. doi: 10.1186/1471-244X-11-87.